Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387023 · ClinicalTrials.gov registry record · NA
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT00387023: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00387023 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387023, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging, clinical examination (slit lamp biomicroscopy and external examination of the conjunctiva), and external photography whenever possible. 2. To establish the safety profile in this patient population using clinical examination including slit lamp biomicroscopy, and evaluation of the tear film with Schirmer's test. 3. To establish the dosimetry for Zevalin in the orbit in the first 3 patients who agree to undergo dosimetry.
Interventions
- DRUG Rituximab
- DRUG Zevalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-02 |
| Est. Completion | 2012-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00387023
The ClinicalTrials.gov registry entry for NCT00387023 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00387023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00387023 about?
NCT00387023 is a clinical study titled "Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma". Primary Objectives: 1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging, clinical examination (slit lamp biomicroscopy and external examination of t...
What is the current status of trial NCT00387023?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2004-02. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00387023?
The interventions under investigation include: Rituximab (DRUG), Zevalin (DRUG).
Who is sponsoring clinical trial NCT00387023?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.